Advertisement
Interested investors may join the call live by dialing (866) 463-5401 fromthe United States or +1 (212) 457-9857 from international locations andentering PIN code 762482#. Investors may also listen to the live call onlineat http://www.edap-tms.com.
Advertisement
Investors unable to join the call can access a playback of the conferencecall by telephone or online. To access the replay, please dial (866) 439-4554or +1 (212) 457-9844 and using access code 334818# beginning one hour afterthe end of the call until March 22, 2007, or visit the company's Web site athttp://www.edap-tms.com.
About EDAP TMS S.A.
EDAP TMS S.A. develops and markets Ablatherm, the most advanced andclinically proven choice for High Intensity Focused Ultrasound (HIFU)treatment of localized prostate cancer. HIFU treatment is shown to be aminimally invasive and effective treatment option with a low occurrence ofside effects. Ablatherm-HIFU is generally recommended for patients withlocalized prostate cancer (stages T1-T2) who are not candidates for surgery orwho prefer an alternative option, or for patients who failed radiotherapytreatment. The company is also developing this technology for the potentialtreatment of certain other types of tumors. EDAP TMS S.A. also produces andcommercializes medical equipment for treatment of urinary tract stones usingExtra-corporeal Shockwave Lithotripsy (ESWL).
For more information on the Company, contact Magnolia Investor Relationsat (972) 801-4900, the Corporate Investor Relations Dept at +33 (0)4 78 26 4046 or see the Company's Web sites at http://www.edap-tms.com andhttp://www.hifu-planet.com.
In addition to historical information, this press release containsforward-looking statements that involve risks and uncertainties. These includestatements regarding the Company's growth and expansion plans. Such statementsare based on management's current expectations and are subject to a number ofuncertainties and risks that could cause actual results to differ materiallyfrom those described in these forward-looking statements. Factors that maycause such a difference include, but are not limited to, those described inthe Company's filings with the Securities and Exchange Commission.Ablatherm-HIFU treatment is in clinical trials but not yet FDA approved ormarketed in the United States.
CONTACT: EDAP TMS S.A. Magnolia Investor RelationsTo sign up for alerts please visit:http://www.b2i.us/irpass.asp?BzID=1053&to=ea&s=0
SOURCE EDAP TMS S.A.
